Skip to main
IRON

IRON Stock Forecast & Price Target

IRON Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 63%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Disc Medicine is well-positioned for success with strong potential for regulatory approval of its novel treatments, including bitopertin for erythropoietic porphyrias and DISC-0974 for anemia of myelofibrosis. Positive interim data from ASCO demonstrate high response rates and rapid and sustained reductions in hepcidin and increases in serum iron. With a clear regulatory path and ongoing clinical progress, the company has a strong outlook for future revenue growth and potential earnings.

Bears say

Disc Medicine is facing a negative outlook due to FDA issuing a Complete Response Letter for their drug bitopertin, citing uncertainty in the link between the drug's biomarker change and clinical benefit despite acknowledging its effectiveness in reducing the biomarker. As a result, their ongoing Phase 3 APOLLO study has been positioned to address these concerns, with topline data expected in 4Q26 and potential approval in mid-2027. However, this delay may impact their financials, with projected sales in 2027-2030 decreasing to $5MM, $103MM, $282MM, and $503MM respectively. Overall, there is limited risk to ultimate approval, but current price action may present an attractive buying opportunity for investors looking beyond the delay.

IRON has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 63% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Disc Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Disc Medicine Inc (IRON) Forecast

Analysts have given IRON a Buy based on their latest research and market trends.

According to 8 analysts, IRON has a Buy consensus rating as of Jul 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $97.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $97.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Disc Medicine Inc (IRON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.